Cologuard Maker Exact Sciences Slashes Outlook as Losses Mount
Exact Sciences shares plunged Wednesday after the maker of Cologuard reported widening losses and cut its outlook.
Exact Sciences: Cancer Detection Stalwart's Bad Quarter Resets Its Overgrown Market Cap.
Exact Sciences may have had disappointing Q3 earnings, but its liquidity cushions and new product approval indicate strong ...
What Is the Age Limit for Medicare Coverage of Cologuard?
Cologuard is an at-home colon cancer screening kit that detects changes in genetic material indicating potential cancer or polyps. Medicare covers one kit per year under Original Medicare (Parts A and ...
Yahoo Finance6d
Cologuard Maker Exact Sciences Slashes Outlook as Losses Mount
The maker of the Cologuard colon cancer screening test lowered its full-year outlook. CEO Kevin Conroy said the firm's quarterly execution and forecast don't reflect its full potential.
Exact Sciences: Q3 Sell-Off May Be Unjustified, But Long-Term Outlook A Concern
Exact Sciences' Q3 report led to a ~25% drop in share price, due to a slight guidance cut and narrow revenue miss. Learn more ...
Dr. Zorba Paster: Choose the colon cancer test that works for you
Let’s start with the cheapest, the yearly FIT, or fecal immunochemical test, which looks for fecal blood that might be caused ...
Exact Sciences Q3 Financial Analysis: Key Earnings and Investor Insights
Detailed price information for Exact Sciences Cor (EXAS-Q) from The Globe and Mail including charting and trades.
Madison.com6d
Madison-based Exact Sciences reports Q3 results short of analysts’ expectations
The biomedical giant best known for its Cologuard at-home colon cancer screening test reported a loss of $38.2 million, or $0.21 per share, on revenue of $708.7 million. The average estimate of six ...
Exact Sciences (NASDAQ:EXAS) Shares Gap Down on Disappointing Earnings
Shares of Exact Sciences Co. (NASDAQ:EXAS – Get Free Report) gapped down prior to trading on Wednesday after the company ...